Last reviewed · How we verify
Apo-Latanoprost
Latanoprost is a prostaglandin F analog that binds to prostaglandin F receptors in the eye to increase uveoscleral outflow of aqueous humor, thereby lowering intraocular pressure.
Latanoprost is a prostaglandin F analog that binds to prostaglandin F receptors in the eye to increase uveoscleral outflow of aqueous humor, thereby lowering intraocular pressure. Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | Apo-Latanoprost |
|---|---|
| Also known as | 02296527 |
| Sponsor | Dr. David Yan |
| Drug class | Prostaglandin F analog |
| Target | Prostaglandin F receptor (FP receptor) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Latanoprost mimics the action of prostaglandin F2α by activating F-prostanoid receptors on the ciliary muscle bundle and trabecular meshwork. This activation enhances drainage of aqueous humor through the unconventional (uveoscleral) pathway, reducing intraocular pressure without significantly affecting aqueous humor production. The drug is administered as a topical ophthalmic solution.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Increased iris pigmentation
- Conjunctival hyperemia
- Eyelash growth (hypertrichosis)
- Eye irritation/discomfort
- Darkening of periocular skin
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Apo-Latanoprost CI brief — competitive landscape report
- Apo-Latanoprost updates RSS · CI watch RSS
- Dr. David Yan portfolio CI